Orchid Pharma Ltd
About
Orchid Pharma Limited is a Chennai based pharmaceutical company that operates across the value chain. The company specialises in the development, manufacture and distribution of active pharmaceutical ingredients (APIs), bulk actives and nutraceuticals. Orchid’s API product line includes veterinary products, non-antibiotics and oral and injectable cephalosporins among others. The company became a subsidiary of Dhanuka Laboratories Limited in 2020. Orchid is the first Indian company to develop a New Chemical Entity (NCE), essentially a new drug, and secure approval from the U.S. Food and Drug Administration (FDA) for the same. Orchid’s manufacturing facility is one of only three in the world authorized by the USFDA to produce cephalosporins.
Featured In Fortune India Ranking
Financial Data 2024
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 894 19.9% | 746 14.1% | 654 35.6% | 482 -8.4% | 526 -33.5% | 791 13.7% | 696 -13.5% | 804 -11.1% | 905 -52.2% | 1893 -5.8% | 2011 -2.7% | 2066 4.1% | 1984 -5.3% | 2094 43.9% | 1455 - |
| Net Operating Income (INR Cr) | 819 23.05% | 666 19.00% | 560 24.33% | 450 -6.97% | 484 -19.36% | 600 -12.15% | 683 -14.25% | 797 -8.81% | 873 -49.99% | 1747 -10.32% | 1948 3.95% | 1874 5.15% | 1782 32.63% | 1343 3.59% | 1297 -0.32% |
| Profit (INR Cr) | 92 99.0% | 46 - | -2 - | -117 - | -131 - | 69 - | -353 - | -495 - | -279 - | -197 - | -558 - | 97 -37.6% | 156 -54.0% | 339 - | -49 - |
| Assets (INR Cr) | 1308 26.7% | 1033 11.5% | 926 -17.1% | 1117 -16.9% | 1344 -47.0% | 2534 4.8% | 2418 -8.6% | 2645 -19.0% | 3267 -7.8% | 3544 -1.3% | 3590 14.0% | 3148 -1.7% | 3203 24.1% | 2581 -20.6% | 3250 - |
| Net Worth (INR Cr) | 1169 69.8% | 689 6.4% | 647 -0.9% | 653 -14.8% | 766 208.8% | -704 11.1% | -792 -69.6% | -467 -1051.8% | 49 -85.1% | 329 -13.3% | 380 -66.4% | 1132 5.9% | 1069 14.0% | 938 48.0% | 634 -4.7% |
| Employee Cost (INR Cr) | 70 6.6% | 65 3.3% | 63 -5.7% | 67 -10.4% | 75 -9.0% | 82 -4.6% | 86 8.6% | 79 -8.5% | 87 -55.2% | 194 -23.3% | 253 43.3% | 176 7.1% | 165 -5.6% | 174 26.9% | 137 - |
| Interest Cost (INR Cr) | 17 | 33 | 33 | 52 | 6 | 7 | 310 | 347 | 294 | 537 | 523 | 180 | 117 | 242 | 156 |
| Cash & Bank Balance (INR Cr) | 267 | 31 | 8 | 20 | 174 | 326 | 306 | 257 | 315 | 391 | 23 | 177 | 201 | 335 | 53 |
| Total Debt (INR Cr) | 135 | 331 | 268 | 453 | 566 | 3230 | 3202 | 3106 | 3215 | 3211 | 3204 | 2005 | 2079 | 1644 | 2616 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 10.3% | 6.2% | - | - | - | 8.8% | - | - | - | - | - | 4.7% | 7.9% | 16.2% | - |
| Profit As % Of Assets | 7.1% | 4.5% | - | - | - | 2.7% | - | - | - | - | - | 3.1% | 4.9% | 13.1% | - |
| Profit As % Of Networth | 7.9% | 6.7% | - | - | - | - | - | - | - | - | - | 8.6% | 14.6% | 36.2% | - |
| Interest Cost to EBITDA % | 15.1% | 42.4% | 61.3% | 177.7% | - | - | 1276.3% | - | 248.9% | 138.2% | 966.0% | 65.9% | 33.9% | - | 91.7% |
| Debt to Equity Ratio | 0.12 | 0.48 | 0.41 | 0.69 | 0.74 | - | - | - | 65.55 | 9.75 | 8.43 | 1.77 | 1.94 | 1.75 | 4.13 |
| RONW | 3.0% | 0.3% | - | - | - | - | - | - | - | - | - | 8.8% | 15.5% | -69.2% | - |
| ROCE | 3.2% | 1.5% | -1.1% | 0.0% | 0.0% | -3.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 8.0% | 10.0% | -10.3% | 0.0% |